2026年9月23日（星期三）
本日收錄 24 篇文獻Future GLP-1 receptor co-agonists and their cardiac effects.
Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only type 2 diabetes and obesity but also cardiac diseases such as coronary heart disease, myocardial in
Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.
OBJECTIVE: This study evaluated temporal trends and patient characteristics associated with glucagon-like peptide-1 (GLP-1) receptor agonist prescribing among US adults without an apparent FDA-approve
Food Insecurity and Its Association with the Spectrum of Steatotic Liver Disease and Hepatic Fibrosis.
The impact of food insecurity on the subtypes of steatotic liver disease (SLD) under the updated nomenclature remains undefined. We aimed to assess the relationship between food insecurity and metabol
Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.
AIMS: Real-world long-term data on oral semaglutide are limited. We evaluated its 24-month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). MATERIALS AND METHODS: This retr
A coherent family support model (Co-Fam) for preventing and treating childhood overweight and obesity: protocol for a randomized hybrid type 2 effectiveness-implementation trial.
BACKGROUND: Swedish child healthcare involves school health services, primary healthcare, and pediatric clinics. Family-based programs addressing child diet, eating behavior, parental feeding practice
Future GLP-1 receptor co-agonists and their cardiac effects.
Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only
Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.
OBJECTIVE: This study evaluated temporal trends and patient characteristics associated with glucagon
Food Insecurity and Its Association with the Spectrum of Steatotic Liver Disease and Hepatic Fibrosis.
The impact of food insecurity on the subtypes of steatotic liver disease (SLD) under the updated nom
Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.
AIMS: Real-world long-term data on oral semaglutide are limited. We evaluated its 24-month effective
A coherent family support model (Co-Fam) for preventing and treating childhood overweight and obesity: protocol for a randomized hybrid type 2 effectiveness-implementation trial.
BACKGROUND: Swedish child healthcare involves school health services, primary healthcare, and pediat
Clinical Tuberculosis: Presentation and Diagnostic Approach.
Tuberculosis (TB) in adults can present in multiple ways. The lung is the most common site of diseas
Implementation and Impact of Nutritional Protocols in Oncology: A Multicenter Evaluation and HCPs' Perspectives on Screening, Intervention, and Monitoring Practices.
BACKGROUND AND AIM: Malnutrition is a prevalent yet under-recognized complication in oncology that a
Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.
OBJECTIVE: To evaluate the emerging role of obesity pharmacotherapies, particularly glucagon-like pe
Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.
INTRODUCTION: Suboptimal clinical response can occur after bariatric surgery. Glucagon-like peptide-
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for Type 2 diabetes (T2DM
Combination pharmacotherapy for MASH: Potential synergistic approaches.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent and severe li
GLP-1 Analogues and Long-term Outcomes in Adults with Obesity and Elevated CRP: A Real-world Matched Cohort Study.
Obesity is frequently accompanied by low-grade systemic inflammation and increased cardiovascular ri
Letter to the Editor: The Gut Microbiome-Endocrine Axis in Obesity: Mechanisms and Therapeutics.
Obesity therapeutics is rapidly evolving, and mechanistic frameworks linking the gut microbiome to s
Personalized obesity hypoventilation syndrome risk assessment among bariatric surgery candidates through explainable machine learning: A multicenter cross-sectional study.
BACKGROUND: Obesity hypoventilation syndrome (OHS) is frequently underdiagnosed, which substantially
High-Intensity Interval Training Modulates NLRP3 Inflammasome-Related Expression and Monocyte Subset Distribution in Adults With Obesity: A Randomised Trial.
To evaluate whether high-intensity interval training (HIIT) modulates NLRP3 inflammasome expression,
Autophagy in hypothalamic POMC and AgRP neurons: mechanisms and therapeutic implications for obesity.
Obesity is increasingly recognized as a disorder involving impaired central endocrine regulation in
IL-1RA administration exerts diet-dependent metabolic effects on adipose tissue function and lipid handling in male mice.
Interleukin-1 (IL-1) signaling is a key mediator of metabolic inflammation, yet its tissue-specific
Impacts of a fresh-frozen dog food on fecal consistency and microbiome in colony dogs.
Fresh-frozen dog diets are becoming increasingly popular among pet owners, but little is known regar
Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index.
Lipoedema is a painful adipose tissue disorder marked by disproportionate limb fat and often misclas
Takayasu Arteritis in a 15-Year-Old Male Presenting with Constitutional Symptoms and Upper Limb Pulse Deficit: A Case Report a Resource-Limited Settings.
BACKGROUND: Takayasu arteritis (TA) is a chronic granulomatous large-vessel vasculitis that primaril
Castleman Disease in Tunisia: A Multicenter Clinical, Prognostic, and Therapeutic Study.
INTRODUCTION: Castleman disease is an uncommon benign lymphoproliferative condition that includes di
Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study.
INTRODUCTION: In people with type 2 diabetes (T2D) without dementia, glucagon-like peptide-1 recepto
Beyond efficacy: health inequities limiting access to semaglutide for obesity management.
摘要 unavailable
Intermittent Fasting in MASLD: Is the Fasting Window the True Intervention?
摘要 unavailable